A Phase 1 Study of ERAS-0015 in People With Solid Tumors

Full Title

A Phase 1 First-in-human Open-label study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients with Advanced Solid Tumors

Purpose

Researchers want to find the highest dose of ERAS-0015 that can be given safely in people with advanced solid tumors. The people in this study have cancer that has metastasized (spread) and has a mutation in the RAS gene.

ERAS-0015 blocks a cell pathway that promotes the growth and spread of cancer. By blocking a group of proteins called RAS proteins, ERAS-0015 may help slow or stop the growth of your cancer. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have a metastatic solid tumor that cannot be cured with standard therapies. Examples include colorectal cancer, non-small cell lung cancer, and pancreatic cancer.
• Have recovered from the serious side effects of previous treatments before taking ERAS-0015.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call 646-888-4226.